Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)

Dr. Sean Grimm

Neurology
Rush University Medical Group
1725 W Harrison St, Suite 1010, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Rush University Medical Group
1725 W Harrison St, Suite 1010, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sean Grimm is a Neurologist in Chicago, Illinois. Dr. Grimm is rated as an Advanced provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in IL
Hospital Affiliations
Rush University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

RUSH UNIVERSITY MEDICAL GROUP
1725 W Harrison St, Suite 1010, Chicago, IL 60612

Additional Areas of Focus

Dr. Grimm has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Procedure, Device, Biological
Study Phase: Phase 2
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Atezolizumab, Tocilizumab
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
Enrollment Status: Completed
Publish Date: August 26, 2022
Intervention Type: Other, Drug
Study Phase: Early Phase 1
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
Enrollment Status: Completed
Publish Date: September 17, 2019
Intervention Type: Procedure, Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

38 Total Publications

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
Journal: Research square
Published: October 03, 2025
Similar Doctors
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Jonathan Johnson
Neurology
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Jonathan Johnson
Neurology

American Neuromonitoring Associates, PC

8307 Creek View Ln, 
Mount Pleasant, WI 
 (60.3 miles away)
888-464-2466
Languages Spoken:
English
See accepted insurances

Jonathan Johnson is a Neurologist in Mount Pleasant, Wisconsin. Dr. Johnson is rated as a Distinguished provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). His top areas of expertise are Cervical Myelopathy, Hemangioblastoma, Spinal Tumor, and Subependymoma.

Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Steven Zak
Neurology
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Steven Zak
Neurology

American Neuromonitoring Associates, PC

1403 Kingsport Ct, 
Northbrook, IL 
 (19.9 miles away)
847-564-1870
Languages Spoken:
English
See accepted insurances

Steven Zak is a Neurologist in Northbrook, Illinois. Dr. Zak is rated as a Distinguished provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). His top areas of expertise are Cervical Myelopathy, Invertebral Disc Disease, Spinal Tumor, and Dysembryoplastic Neuroepithelial Tumors (DNET).

Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Neal B. Patel
Neurosurgery | Neurology
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Neal B. Patel
Neurosurgery | Neurology

Beacon Medical Group Inc

900 I St, 
La Porte, IN 
 (52.1 miles away)
219-324-1700
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neal Patel is a Neurosurgery specialist and a Neurologist in La Porte, Indiana. Dr. Patel has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). His top areas of expertise are Dysembryoplastic Neuroepithelial Tumors (DNET), Brain Stem Cancer, Subdural Hematoma, Microdiscectomy, and Cervical Disc Surgery. Dr. Patel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grimm's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile